Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic Connectivity Under Metabolic Constraints
NCT04840095Phase 4Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2015
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in insulin resistance (IR) and brain aging, sponsored by Massachusetts General Hospital. Primary endpoint: fMRI stability measures: endogenous ketones vs exogenous glucose at 2 weeks. Status: unknown.
02
Conditions
insulin resistance (IR)brain aging
Beyond the preview
Go deeper on NCT04840095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840095.